RWC Asset Advisors (US) LLC disclosed a sale of 834,689 shares of Kanzhun Limited (BZ +1.72%) in its February 17, 2026, SEC filing, an estimated $18.03 million trade based on quarterly average pricing. What happened According to an SEC filing dated February 17, 2026, RWC Asset Advisors (US) LLC reduced its holdings in Kanzhun Limited by 834,689 shares during the final quarter of 2025. The estimate...
RWC Asset Advisors (US) LLC disclosed a sale of 834,689 shares of Kanzhun Limited (BZ +1.72%) in its February 17, 2026, SEC filing, an estimated $18.03 million trade based on quarterly average pricing. What happened According to an SEC filing dated February 17, 2026, RWC Asset Advisors (US) LLC reduced its holdings in Kanzhun Limited by 834,689 shares during the final quarter of 2025. The estimated transaction value, based on the period’s average closing price, was $18.03 million. The quarter-end value of the Kanzhun Limited position dropped by $24.00 million, a figure that includes both the effect of share sales and market price changes. What else to know This sell action lowered the Kanzhun Limited stake to 5.83% of RWC Asset Advisors (US) LLC’s 13F reportable AUM, down from 8.96% in the previous quarter. Top holdings after the filing: NYSE:SQM: $100.64 million (19.1% of AUM) NYSE:VALE: $85.00 million (16.1% of AUM) NYSE:EMBJ: $79.76 million (15.1% of AUM) NYSE:GFI: $75.57 million (14.3% of AUM) NYSE:BABA: $66.01 million (12.5% of AUM) As of Friday, Kanzhun Limited shares were priced at $13.63, down 34% over the past year and well underperforming the S&P 500, which is instead up 15% in the same period. Company overview Metric Value Price (as of Friday) $13.63 Market Capitalization $6 billion Revenue (TTM) $1.16 billion Net Income (TTM) $360.59 million Company snapshot Kanzhun Limited operates BOSS Zhipin, an online recruitment platform connecting job seekers and employers in China, generating revenue primarily from recruitment services and value-added offerings. The firm monetizes through service fees paid by enterprises and corporations for access to candidates and recruitment tools, leveraging a digital platform model. It targets businesses of all sizes and individual job seekers across the Chinese labor market, with a focus on efficient matching and direct communication. Kanzhun Limited is a leading provider of online recruitment solutions in China, leveraging ...
A strike on a healthcare facility in Sudan has killed 64 people and wounded 89 more, the World Health Organization reported on Saturday. The deceased included 13 children, WHO Director-General Tedros Adhanom Ghebreyesus said on social media. The UN’s humanitarian office in Sudan had earlier said it was “appalled by the attack on a hospital in East Darfur yesterday, reportedly killing dozens, incl...
A strike on a healthcare facility in Sudan has killed 64 people and wounded 89 more, the World Health Organization reported on Saturday. The deceased included 13 children, WHO Director-General Tedros Adhanom Ghebreyesus said on social media. The UN’s humanitarian office in Sudan had earlier said it was “appalled by the attack on a hospital in East Darfur yesterday, reportedly killing dozens, including children, and injuring more”. Sudanese rights group the Emergency Lawyers, who document atrocities in the war between Sudan’s army and the paramilitary Rapid Support Forces, reported it was an army drone strike that hit the El-Daein Teaching Hospital. Advertisement The RSF dominates the vast western Darfur region, while the army is in control of Sudan’s east, centre and north. The WHO’s Surveillance System for Attacks marked Friday’s incident as “confirmed” but did not give an exact location. The attack involved “violence with heavy weapons” and affected a secondary healthcare facility, medical personnel, patients, supplies and storage, the record showed. 02:32 Sudan fighters occupying laboratory have raised ‘huge biological risk’, WHO says Sudan fighters occupying laboratory have raised ‘huge biological risk’, WHO says Though the WHO counts and verifies attacks on healthcare, it does not attribute blame as it is not an investigative agency.
Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Microsoft is overhauling leadership around its Copilot AI, unifying consumer and enterprise teams under a new executive and reducing the role of former AI lead Mustafa Suleyman. The company is tightening access to premium Copilot features so that they are av...
Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Microsoft is overhauling leadership around its Copilot AI, unifying consumer and enterprise teams under a new executive and reducing the role of former AI lead Mustafa Suleyman. The company is tightening access to premium Copilot features so that they are available only to paying customers, shifting away from broad bundling into existing products. In parallel, Microsoft is progressing on next generation AI infrastructure, validating Nvidia's Vera Rubin NVL72 systems, expanding data centers, and engaging in new industry partnerships and standards. Microsoft (NasdaqGS:MSFT) is emphasizing AI as a core business line, while its share price stands at $381.87. Over the past 3 years the stock has returned 39.3%, and over 5 years 68.3%, putting Copilot and AI infrastructure decisions in clear focus for many existing shareholders. Recent moves around Copilot monetization and AI infrastructure indicate that Microsoft is defining clearer commercial boundaries around its AI products and allocating more capital to the underlying compute stack. For investors watching AI related spending and revenue contributions, these changes create new markers to track across product adoption, pricing, and long term infrastructure commitments. Stay updated on the most important news stories for Microsoft by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Microsoft. NasdaqGS:MSFT 1-Year Stock Price Chart Does the team leading Microsoft have what it takes? See our full breakdown of the management team's track record and compensation. Investor Checklist Quick Assessment ✅ Price vs Analyst Target : At US$381.87, the price sits about 36% below the US$594.62 analyst target. ✅ Simply Wall St Valuation : Shares are described as trading 14.5% below an estimated fair value. ❌ Recent Momentum: The 30 day...
Micron (MU 4.89%) reported fantastic quarterly financial results, yet the stock is still falling. *Stock prices used were the afternoon prices of March 19, 2026. The video was published on March 21, 2026.
Micron (MU 4.89%) reported fantastic quarterly financial results, yet the stock is still falling. *Stock prices used were the afternoon prices of March 19, 2026. The video was published on March 21, 2026.
One reality television insider, who asked not to be identified due to their ties to the involved parties, said the network was "willing to put all the chips in the middle of the table" because if it worked out well, The Bachelorette could have acquired an entirely new audience with a valuable new demographic.
One reality television insider, who asked not to be identified due to their ties to the involved parties, said the network was "willing to put all the chips in the middle of the table" because if it worked out well, The Bachelorette could have acquired an entirely new audience with a valuable new demographic.
Qualcomm NASDAQ: QCOM held its 2026 annual meeting of stockholders on Thursday, with Chair Mark McLaughlin opening the session by introducing board nominees and members of the executive team, including President and CEO Cristiano Amon and CFO/COO Akash Palkhiwala. McLaughlin also recognized two departing directors: Neil Smit, who is retiring after nearly eight years on the board, and Chris Young, ...
Qualcomm NASDAQ: QCOM held its 2026 annual meeting of stockholders on Thursday, with Chair Mark McLaughlin opening the session by introducing board nominees and members of the executive team, including President and CEO Cristiano Amon and CFO/COO Akash Palkhiwala. McLaughlin also recognized two departing directors: Neil Smit, who is retiring after nearly eight years on the board, and Chris Young, who is leaving to focus on his role as CEO of Vertex Incorporated. Get Qualcomm alerts: Sign Up Governance items and voting outcomes General Counsel and Corporate Secretary Ann Chaplin reviewed procedural matters, including confirmation that a quorum was present and that Peter Descovich had been appointed inspector of election. Stockholders considered seven proposals, and management reported preliminary results showing all board-recommended items were approved while the two stockholder proposals were not. Director elections: Stockholders elected all 11 director nominees: Sylvia Acevedo, Cristiano Amon, Mark Fields, Jeff Henderson, Zico Kolter, Ann Livermore, Mark McLaughlin, Jamie Miller, Marie Myers, Irene Rosenfeld, and Jean-Pascal Tricoire. Stockholders elected all 11 director nominees: Sylvia Acevedo, Cristiano Amon, Mark Fields, Jeff Henderson, Zico Kolter, Ann Livermore, Mark McLaughlin, Jamie Miller, Marie Myers, Irene Rosenfeld, and Jean-Pascal Tricoire. Auditor ratification: Stockholders ratified PricewaterhouseCoopers LLP as independent public accountants for the fiscal year ending September 27, 2026. Stockholders ratified PricewaterhouseCoopers LLP as independent public accountants for the fiscal year ending September 27, 2026. Executive compensation: Stockholders approved the non-binding advisory “say-on-pay” proposal. Stockholders approved the non-binding advisory “say-on-pay” proposal. Say-on-pay frequency: Stockholders supported holding future say-on-pay votes on an annual basis. Stockholders supported holding future say-on-pay votes on an annual basis. Equit...
Iran's own Atomic Energy Organisation (AEOI) described the attack on Natanz as a violation of the Treaty on the Non-Proliferation of Nuclear Weapons, though it said "no leakage of radioactive materials" was reported and there was "no danger to residents of the surrounding areas".
Iran's own Atomic Energy Organisation (AEOI) described the attack on Natanz as a violation of the Treaty on the Non-Proliferation of Nuclear Weapons, though it said "no leakage of radioactive materials" was reported and there was "no danger to residents of the surrounding areas".
Volkswagen AG ’s chief executive officer said the restructuring process underway at Europe’s largest automaker will continue even as its order backlog rises, according to Bild am Sonntag. To avoid costly overcapacity, VW is applying “clear manufacturing cost targets” to all its plants, be they in Germany, Europe or China, Oliver Blume told the German newspaper in an interview. “We will continue to...
Volkswagen AG ’s chief executive officer said the restructuring process underway at Europe’s largest automaker will continue even as its order backlog rises, according to Bild am Sonntag. To avoid costly overcapacity, VW is applying “clear manufacturing cost targets” to all its plants, be they in Germany, Europe or China, Oliver Blume told the German newspaper in an interview. “We will continue to scrutinize capacities in the future,” Blume said. “The restructuring will continue,” he said, while defending the company’s plan to cut about 50,000 jobs in Germany by 2030. VW has a higher cost structure in its home market, including labor costs, “and we have to offset that with higher productivity,” Blume was cited as saying. “Our energy costs are too high and there’s too much regulation,” he said. “Developing and building vehicles in Germany and then exporting them doesn’t work any more because the various regions of the world have changed,” he said. VW has forecast an operating return this year as low as 4% as tariffs, spending on electric vehicles and intensifying competition from China drag on its business. Read More: VW Targets More Savings to Keep Up With Intense Competition
Sir Jim Ratcliffe’s Ineos Group is taking legal action against Sir Ben Ainslie over the boat built for the 2024 America’s Cup. Ratcliffe and Ainslie worked closely together across two cycles of the famous sailing competition, culminating in a historic but ultimately unsuccessful challenge for the title 18 months ago. The two men have since fallen out over plans for a third bid. In April 2025, Ineo...
Sir Jim Ratcliffe’s Ineos Group is taking legal action against Sir Ben Ainslie over the boat built for the 2024 America’s Cup. Ratcliffe and Ainslie worked closely together across two cycles of the famous sailing competition, culminating in a historic but ultimately unsuccessful challenge for the title 18 months ago. The two men have since fallen out over plans for a third bid. In April 2025, Ineos announced it had “reluctantly withdrawn its challenge” for next year’s race, claiming a six-month delay in reaching an agreement with Ainslie’s Athena Racing had “undermined its ability to prepare” for the event. On Saturday, Ineos released a statement on Saturday expressing “surprise” that Ainslie’s Athena Racing has kept the boat – named Britannia – which was used in 2024. Ineos Britannia became the first British team to win the challenger series but were then beaten 7-2 by Emirates Team New Zealand in Barcelona. “Ineos is surprised that the boat we built for the last America’s Cup has been taken by Athena Racing,” read the statement. “The boat belongs to Ineos and it is inappropriate to assume it can be used for the next competition without seeking our permission. View image in fullscreen Ineos Britannia race Emirates New Zealand off the coast of Barcelona in 2024. Photograph: Matteo Secci/Zuma/Shutterstock “The boat was the most successful British boat in history and cost Ineos £180million, and evolved naturally from the first boat, which cost a further £170m. Ineos is taking legal steps for the boat to be returned.” Ainslie’s team, now rebranded as GB1, will be the challenger of record for the 38th America’s Cup in Naples next year, with Oakley Capital announced as major investors in December. Later on Saturday GB1 issued a statement in response, in which they said they “appreciate the sponsorship and support of Ineos over the last two campaigns” but maintained the boat belonged to them. “It should come as no surprise to Ineos that assets which are owned by, and have...
Reddit (NYSE: RDDT) is one of the fastest-growing social media companies in the world. *Stock prices used were the afternoon prices of March 19, 2026. The video was published on March 21, 2026. Continue reading
Reddit (NYSE: RDDT) is one of the fastest-growing social media companies in the world. *Stock prices used were the afternoon prices of March 19, 2026. The video was published on March 21, 2026. Continue reading
On February 17, 2026, FCPM III Services B.V. disclosed a buy of 1,489,096 RAPT Therapeutics (NASDAQ:RAPT) shares, an estimated $46.24 million trade based on quarterly average pricing. According to a Securities and Exchange Commission (SEC) filing dated February 17, 2026, FCPM III Services B.V. increased its stake in RAPT Therapeutics (NASDAQ:RAPT) by 1,489,096 shares during the fourth quarter. The...
On February 17, 2026, FCPM III Services B.V. disclosed a buy of 1,489,096 RAPT Therapeutics (NASDAQ:RAPT) shares, an estimated $46.24 million trade based on quarterly average pricing. According to a Securities and Exchange Commission (SEC) filing dated February 17, 2026, FCPM III Services B.V. increased its stake in RAPT Therapeutics (NASDAQ:RAPT) by 1,489,096 shares during the fourth quarter. The estimated value of the new shares acquired was $46.24 million, based on the average unadjusted closing price for the quarter. At quarter-end, the total value of the position had risen by $53.22 million, reflecting both the trading activity and changes in RAPT’s share price. RAPT Therapeutics, Inc. is a clinical-stage biotechnology company specializing in the development of oral small molecule drugs for cancer and inflammatory conditions. The company's strategy centers on advancing novel CCR4 antagonists and kinase inhibitors through clinical trials to address significant unmet needs in immunology and oncology. Continue reading
For several months, I had been warning investors that SoFi (NASDAQ: SOFI) stock was too expensive. Since my warnings, the stock has crashed to lower levels. *Stock prices used were the afternoon prices of March 19, 2026. The video was published on March 21, 2026. Continue reading
For several months, I had been warning investors that SoFi (NASDAQ: SOFI) stock was too expensive. Since my warnings, the stock has crashed to lower levels. *Stock prices used were the afternoon prices of March 19, 2026. The video was published on March 21, 2026. Continue reading
After becoming the first healthcare stock to hit a $1 trillion market valuation in late 2025, Eli Lilly (LLY 1.29%) hasn't performed well since, with its shares down about 19% from their 52-week high of $1133.95. Some are worried about the company's runaway valuation, while others fear that, even as the drugmaker leads the market for weight management medicines, increased competition will erode it...
After becoming the first healthcare stock to hit a $1 trillion market valuation in late 2025, Eli Lilly (LLY 1.29%) hasn't performed well since, with its shares down about 19% from their 52-week high of $1133.95. Some are worried about the company's runaway valuation, while others fear that, even as the drugmaker leads the market for weight management medicines, increased competition will erode its pricing power and depress its profits and margins. The bulls might have a different view, though, but which side is right? The expanding anti-obesity market While it's true that there will be more competition in chronic weight management, Eli Lilly's lead in this space seems safe. What's more, newer launches will help the company solidify its top position while expanding its addressable market. Take orforglipron, an oral GLP-1 candidate Eli Lilly is gearing up to launch, hopefully in the second quarter. As management noted, the only oral therapy currently approved for weight loss, oral Wegovy, is attracting new patients, likely those who did not want to take older subcutaneous weight-loss medications. Orforglipron could be a best-in-class medicine thanks to its strong clinical trial performance across both diabetes and obesity, including some studies in which it went head-to-head with other oral GLP-1s and performed better. Eli Lilly could also target an underserved niche with another candidate, retatrutide. In a phase 3 study, not only did retatrutide lead to an outstanding 28.7% mean weight loss after 68 weeks -- a number never before seen in a phase 3 clinical trial -- but it also significantly reduced knee pain. Eli Lilly will target patients with high body mass indexes -- for whom current weight-loss options often plateau, leaving them with plenty of work to do -- with this drug. Expand NYSE : LLY Eli Lilly Today's Change ( -1.29 %) $ -11.87 Current Price $ 905.63 Key Data Points Market Cap $857B Day's Range $ 899.48 - $ 925.00 52wk Range $ 623.78 - $ 1133.95 Volume ...
Key Points Eli Lilly is well-positioned to maintain its lead in the anti-obesity market. The company's newer products in this niche will help expand its reach. Eli Lilly has an attractive lineup and pipeline beyond its core area. 10 stocks we like better than Eli Lilly › After becoming the first healthcare stock to hit a $1 trillion market valuation in late 2025, Eli Lilly (NYSE: LLY) hasn't perfo...
Key Points Eli Lilly is well-positioned to maintain its lead in the anti-obesity market. The company's newer products in this niche will help expand its reach. Eli Lilly has an attractive lineup and pipeline beyond its core area. 10 stocks we like better than Eli Lilly › After becoming the first healthcare stock to hit a $1 trillion market valuation in late 2025, Eli Lilly (NYSE: LLY) hasn't performed well since, with its shares down about 19% from their 52-week high of $1133.95. Some are worried about the company's runaway valuation, while others fear that, even as the drugmaker leads the market for weight management medicines, increased competition will erode its pricing power and depress its profits and margins. The bulls might have a different view, though, but which side is right? Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue » The expanding anti-obesity market While it's true that there will be more competition in chronic weight management, Eli Lilly's lead in this space seems safe. What's more, newer launches will help the company solidify its top position while expanding its addressable market. Take orforglipron, an oral GLP-1 candidate Eli Lilly is gearing up to launch, hopefully in the second quarter. As management noted, the only oral therapy currently approved for weight loss, oral Wegovy, is attracting new patients, likely those who did not want to take older subcutaneous weight-loss medications. Orforglipron could be a best-in-class medicine thanks to its strong clinical trial performance across both diabetes and obesity, including some studies in which it went head-to-head with other oral GLP-1s and performed better. Eli Lilly could also target an underserved niche with another candidate, retatrutide. In a phase 3 study, not only did retatrutide lead to an outstanding 28.7% mean wei...
Round-the-clock gyms have mushroomed across Hong Kong in recent years, offering flexibility and convenience to time-pressed people juggling work and exercise. But just like the notorious problems of aggressive sales tactics and long membership contracts with chain fitness centres in the industry’s heyday, these smaller outlets running on a new business model also come with hidden costs and privacy...
Round-the-clock gyms have mushroomed across Hong Kong in recent years, offering flexibility and convenience to time-pressed people juggling work and exercise. But just like the notorious problems of aggressive sales tactics and long membership contracts with chain fitness centres in the industry’s heyday, these smaller outlets running on a new business model also come with hidden costs and privacy issues that consumers cannot afford to ignore. A targeted investigation by the Consumer Council on 24-hour operators has exposed how simple monthly plans can conceal a maze of extra costs . Five of the 11 gyms examined had non-refundable charges such as enrolment fees and payments for electronic keys or access cards. None offered genuine “one-month membership” as advertised, and the real price for short-term memberships can be more than double the headline monthly fees. The conditions for suspending membership also vary widely. There is a sense of deja vu. Previously, the council hit out at the long binding contracts and aggressive sales tactics that locked users of chain fitness centres into disadvantaged positions. While the industry has evolved into smaller outlets with 24/7 operations, the problems with opaque fee structures and complicated tie-ins prevail. Advertisement All-day access also comes with security and privacy concerns, with users required to provide sensitive personal data to enter the premises via facial recognition or other biometric systems. The watchdog has rightly reminded gym operators to adhere to the principle of collecting “necessary and adequate but not excessive” personal data and consider less privacy-intrusive methods for sign-up and access. Consumers are also urged to scrutinise the sales and privacy terms to avoid misunderstanding and abuses. In a city where digital footprints are expanding rapidly, the collection of facial images in exchange for convenient and value-for-money fitness facilities should not be treated lightly. The onus is on ...
Key Points Kynam Capital sold 1,720,949 shares of Cogent Biosciences in the fourth quarter; the estimated transaction value was $48.38 million. Meanwhile, the position's quarter-end value changed by $105.74 million, reflecting both trading and share price movements. Post-sale, the fund held 6,165,223 shares valued at $218.99 million. 10 stocks we like better than Cogent Biosciences › Kynam Capital...
Key Points Kynam Capital sold 1,720,949 shares of Cogent Biosciences in the fourth quarter; the estimated transaction value was $48.38 million. Meanwhile, the position's quarter-end value changed by $105.74 million, reflecting both trading and share price movements. Post-sale, the fund held 6,165,223 shares valued at $218.99 million. 10 stocks we like better than Cogent Biosciences › Kynam Capital Management disclosed in a February 17, 2026, SEC filing that it sold 1,720,949 shares of Cogent Biosciences (NASDAQ:COGT), an estimated $48.38 million trade based on quarterly average pricing. What happened According to a SEC filing dated February 17, 2026, Kynam Capital Management reduced its stake in Cogent Biosciences by 1,720,949 shares during the fourth quarter. The estimated transaction value was $48.38 million, calculated using the average closing price over the quarter. The quarter-end valuation of this position changed by $105.74 million, a figure that incorporates both share sales and stock price appreciation. What else to know Kynam Capital Management, LP’s sell action left Cogent Biosciences at 13.99% of reported AUM after the trade. Top holdings after the filing: NASDAQ:COGT: $218.99 million (14.3% of AUM) NASDAQ:VERA: $173.85 million (11.3% of AUM) NASDAQ:SNDX: $169.15 million (11.0% of AUM) NASDAQ:CLDX: $161.42 million (10.5% of AUM) NASDAQ:PCVX: $134.84 million (8.8% of AUM) As of Friday, shares of Cogent Biosciences were priced at $33.38, up a staggering 360% over the past year, compared to a 15% gain for the S&P 500 in the same period. Company overview Metric Value Price (as of Friday) $33.38 Market Capitalization $5.4 billion Net Income (TTM) ($328.94 million) Company snapshot Cogent Biosciences develops precision therapies targeting genetically defined diseases, with a lead product candidate (CGT9486) focused on inhibiting the KIT D816V mutation in systemic mastocytosis and advanced gastrointestinal stromal tumors. The company operates a research-driven...
Key Points Whalen sold 26,667 shares on March 2, 2026, for a transaction value of ~$1.25 million, with an additional 650 shares gifted to charity. The transaction represented 19.9% of Whalen's direct holdings prior to the sale, reducing her direct position to 107,591 shares. All shares disposed were held directly; the transaction included the exercise of 11,667 options immediately prior to sale, w...
Key Points Whalen sold 26,667 shares on March 2, 2026, for a transaction value of ~$1.25 million, with an additional 650 shares gifted to charity. The transaction represented 19.9% of Whalen's direct holdings prior to the sale, reducing her direct position to 107,591 shares. All shares disposed were held directly; the transaction included the exercise of 11,667 options immediately prior to sale, with no indirect or trust involvement. This activity reflects routine liquidity management, with the shares sold comprising a mix of existing holdings and same-day exercised options, and Whalen retains a material direct equity stake. 10 stocks we like better than Bristow Group › SVP CFO Sells VTOL 26,667 Shares Worth $1.25 Million. Bristow Group, a global aviation services provider to offshore energy firms, reported a notable insider sale in its latest SEC filing. On March 2, 2026, Jennifer Dawn Whalen, SVP, CFO of Bristow Group Inc. (NYSE:VTOL), executed the open-market sale of 26,017 shares of common stock for a transaction value of approximately $1.22 million, as disclosed in a SEC Form 4 filing SEC Form 4 filing.This figure excludes 650 shares gifted in the same filing. Transaction summary Metric Value Shares sold (direct) 26,667 Shares gifted (direct) 650 Transaction value ~$1.25 million Post-transaction shares (direct) 107,591 Post-transaction shares (indirect) 0 Post-transaction value (direct ownership) ~$5.05 million Transaction value based on SEC Form 4 weighted average purchase price ($46.90); post-transaction value based on March 2, 2026 market close price as reported in filings.Gift shares: 650 shares gifted in this filing are excluded from all share counts, transaction values, and post-transaction balances above. Key questions What was the structure and derivative context of this transaction? The filing indicates Whalen exercised 11,667 fully vested options at $24.54, immediately selling those shares alongside approximately 14,350 shares from existing holdings. ...
Key Points Uber’s advertising business is scaling faster than expected. This jump in advertising could improve Uber’s margins. Uber’s platform gives it a structural advantage in ads. 10 stocks we like better than Uber Technologies › Investors typically think of Uber Technologies (NYSE: UBER) as a ride-hailing and food delivery company. And for good reason -- those businesses still drive the majori...
Key Points Uber’s advertising business is scaling faster than expected. This jump in advertising could improve Uber’s margins. Uber’s platform gives it a structural advantage in ads. 10 stocks we like better than Uber Technologies › Investors typically think of Uber Technologies (NYSE: UBER) as a ride-hailing and food delivery company. And for good reason -- those businesses still drive the majority of its revenue and growth. But beneath the surface, a quieter business is starting to take shape. And it could become one of Uber's most important profit drivers over time. That business is advertising. Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue » A small segment with bigger-than-expected potential Uber's advertising business started as a simple idea: Help restaurants promote their listings within the Uber Eats app. For years, management viewed this as a useful but limited monetization tool. In fact, the company once believed advertising penetration in delivery would top out at around 2% of gross bookings. But that assumption is already proving too conservative. On its latestearnings call Uber said advertising penetration has already exceeded that 2% level (over $2 billion annualized revenue run rate), and the opportunity is now "much larger" than initially expected. That shift matters. When management raises its view of a business's long-term potential, it often signals that early results are exceeding expectations. And in Uber's case, the drivers of that upside are becoming clearer. Why is advertising so powerful? Unlike rides or deliveries, advertising doesn't require drivers, vehicles, or logistics. It simply monetizes demand that already exists on the platform. That makes it a fundamentally different kind of business. Every time a user opens the app to order food or request a ride, Uber has an ...